ArticleScientific reports2026
Real-life multicenter experience of long-term treatment with venetoclax plus azacitidine for acute myeloid leukemia in China.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Host Fitness: A Missing Dimension of Precision Medicine in Older Acute Myeloid Leukemia.Hematological oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The combination of venetoclax (VEN) and azacitidine (AZA) has transformed the treatment of acute myeloid leukemia (AML) in patients ineligible for intensive therapy. Nevertheless, real-world evidence on long-term outcomes in patients with AML treated with VEN + AZA remains limited. A retrospective analysis was conducted on 79 patients with naïve AML who received at least 6 cycles of VEN + AZA across five collaborating hematology units in China between September 2021 and October 2024. The median age at diagnosis was 67 years (range: 49–87), and the median number of VEN treatment cycles was 9 (range: 6–20). The CR/CRi occurred in 56 of 79 patients (70.9%), with higher rates observed in those harboring NPM1 (80.9%) and IDH2 (80.0%) mutations. The median overall survival (OS) reached 33.5 months, with a median follow-up of 14 months and a median duration of response of 25.4 months. Patients aged over 65 demonstrated inferior OS compared with younger patients (median OS: 26.1 months and not reached, respectively). Patients with NPM1 and IDH2 mutations were associated with improved OS, although the difference did not reach statistical significance. Patients treated with a lower dose of VEN achieved superior OS compared to those receiving the standard dose (P = 0.032). Prolonged VEN + AZA therapy is effective for AML, achieving sustained remission in a subset of patients and supporting its role as a viable maintenance therapy in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.